The COVID-19 pandemic has severely impaired the overall pharmaceutical supply chain, mostly owing to the absence of workers at manufacturing sites and restrictions imposed on distribution networks. In this context, continuous manufacturing offers a viable solution given the fact that continuous processes are largely automated. In fact, the FDA (and other regulatory bodies) have also expressed interest in advocating a shift to the use of advanced manufacturing technologies, such as continuous manufacturing.

To order this 310+ page report, which features 110+ figures and 200+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/continuous-manu...

The USD 1.9 billion (by 2030) financial opportunity within the continuous manufacturing market has been analyzed across the following segments:
 Purpose of Manufacturing
 In-House
 Contract service

 Scale of Operation
 Commercial
 Preclinical / Clinical

 Type of Continuous Manufacturing related Service
 API Manufacturing
 End Product manufacturing

 Type of Drug Molecule
 Biologic
 Small Molecule

 Type of dosage form
 Solid
 Liquid

 Key Geographical Regions
 North America
 Europe
 Asia Pacific

The Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030.” report features the following companies, which we identified to be key players in this domain:
 AbbVie Contract Manufacturing
 Ajinomoto Bio-Pharma Services
 Almac
 Boehringer Ingelheim BioXcellence
 Cambrex
 CordonPharma
 Hovione
 Kaneka
 Lonza
 Patheon
 SK biotek

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Companies with Expertise in Continuous Manufacturing in North America: Profiles

6. Companies with Expertise in Continuous Manufacturing in Europe: Profiles

7. Companies with Expertise in Continuous Manufacturing in Asia-Pacific: Profiles

8. Recent Partnerships and Collaborations

9. Recent Expansions

10. Capacity Analysis

11. Academic Grant Analysis

12. Patent Analysis

13. Initiatives of Companies with In-House Continuous Manufacturing Capabilities

14. Case Study: Modular Facilities in pharmaceutical / Biotechnological Industry

15. Case Study: Technology and Equipment Providers

16. Case Study: Roadmap for the Adoption of Continuous Manufacturing Processes

17. Market Forecast and Opportunity Analysis

18. Conclusion

19. Executive Insights

20. Appendix 1: Tabulated Data

21. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/continuous-manu...

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]